stage 2 breast cancer chemotherapy treatment

... treated for metastatic breast cancer in 4 French cancer centres. The diagnosis of metastasis was made between 19 92 and 20 02. A total of 7 72 patients received first-line chemotherapy [4]. Because ... AM et al. Cancer incidence and mortality in France over the period 1978 -20 00. Rev Epidemiol Sante Publique 20 03;51(1 Pt 1):3-30 2. Dickson R, Pestell R, Lippman M. Metastatic breast cancer. ... Rosenberg S, eds. Cancer Principles and practice of oncology, 7 ed. Philadelphia: Lippincot company. 20 05:1453- 62 3. Ellis M, Hayes D, Lippman M. Treatment of metastatic breast cancer. In: Harris...

Ngày tải lên: 08/08/2014, 17:20

Ngày tải lên: 09/08/2014, 04:21

Ngày tải lên: 13/08/2014, 11:22

... about your cancer or cancer treatment, please call the American Cancer Society anytime day or night at 1-800-ACS -23 45. If a woman and her doctor choose a mas- tectomy as her breast cancer treatment, ... Bisphosphonates Bisphosphonates are used in breast cancer treatment to strengthen bones that have been weakened by invading breast cancer cells. The most commonly used bisphosphonates in breast cancer treatment are pamidronate and ... 5 centimeters (2 inches) and can’t be shrunk by treatment before surgery 43 Stage I, II, and Some Stage III Breast Cancer (continued) NOTES should be given to the area that the breast was removed...

Ngày tải lên: 06/03/2014, 01:20

... Axilla 18 2. 4 Preoperative Staging of the Axilla 21 2. 5 Providing Information and Psychological Support 24 3 Surgery for early breast cancer 29 3.1 Surgery to the Breast 29 3 .2 Surgery ... comprises 24 papers: three systematic reviews (Tatrow and Montgomery, 20 06, Bantum et al., 20 07 and Zimmermann et al., 20 07) 20 RCTs (Allard, 20 07, Allen et al., 20 02, Andersen et al., 20 04, Antoni ... 0 1000 20 00 3000 4000 5000 6000 7000 0 2 4 6 8 10 121 4161 820 222 426 28 Days sedosipe fo rebmuN Biopsy Other Excision Mastectomy Figure 1.7 Length of stay for three main procedures, 20 05/06. Data source: NATCANSAT....

Ngày tải lên: 22/03/2014, 16:21

... symptoms 22 1.14 Follow-up 24 2 Notes on the scope of the guidance 26 3 Implementation 27 4 Research recommendations 28 4.1 Psychological support 28 4 .2 Optimum treatment of the axilla 28 4.3 ... ‘Familial breast cancer (NICE clinical guideline 41 [20 06]). NICE clinical guideline 80 – Early and locally advanced breast cancer 7 Introduction Breast cancer is the most common cancer for ... of the breast cancer clinical team should have completed an accredited communication skills training programme. 1 .2. 2 All patients with breast cancer should be assigned to a named breast care...

Ngày tải lên: 22/03/2014, 16:21

... 55 72 9.4 94 12. 0 24 7.4 190 10.1 55 to 64 183 23 .9 21 5 27 .4 71 21 .9 469 25 .0 65 to 74 27 7 36 .2 238 30.3 138 42. 6 653 34.8 75 to 84 184 24 .1 187 23 .8 74 22 .8 445 23 .7 85 and over 49 6.4 52 6.6 ... (n, %) Breast cancer 92 31% 198 34% 63 28 % 353 32. 0% Endometrial cancer 85 29 % 151 26 % 41 18% 27 7 25 .1% Breast or cancer a 28 9% 9 2% 0 0% 37 3.4% All other causes b, c 90 31% 22 6 39% 121 54% ... 60,000 56 29 4 1.40 0.97, 2. 02 23 23 0 0.91 0.55, 1.51 31 59 1.64 0.94, 2. 87 ≥ 60,000 52 230 1.40 0.95, 2. 05 32 185 1 .29 0.81, 2. 07 18 41 1 .26 0.68, 2. 36 Used, amount unknown 20 84 2. 13 1 .26 , 3.58...

Ngày tải lên: 29/03/2014, 01:20

... 1. Q: How can breast cancer affect bone health? A: Breast cancer can affect bone in two ways: ― Breast cancer can spread (metastasize) to bone. ― Breast cancer treatment can cause ... Risk of Breast Cancer Returning and Where 2. Q: How often does breast cancer that has been treated return? A: The chance of breast cancer returning depends on the type of breast cancer and ... relationship between breast cancer and bone health: ― The relationship between breast cancer and bone health (page 2) . ― The risk of breast cancer returning and where (page 2) . ― Decreasing...

Ngày tải lên: 29/03/2014, 01:20

... 22 96,88 23 10,09 3,37 6 .25 e-14 1.88e-11 78% D 25 54.37 25 40. 32 2568.41 7.16 4.13e-07 1 .24 e-04 1% U 28 45.58 28 38.34 28 52. 81 3.69 3.59e- 12 1.08e-09 21 % D 28 65.54 28 64.46 28 66. 62 7.73 4.19e -20 1 .26 e-17 ... 15.8 3 024 .45 11.71 0.073 32. 8 324 9.64 5 .24 0.075 12. 4 N – nodal status N0 (n = 63)vs. N1 (n = 20 ) 8618 .25 10.83 0. 024 45.1 86 02. 25 29 .35 0.036 29 .5 29 09.04 10.58 0.038 32. 5 8607.98 5.60 0.040 25 .7 86 82. 92 ... 19.9 4098.35 25 .90 0.0 32 22. 5 3 024 .45 11.71 0.035 20 .2 4070.43 5.58 0.048 19 .2 T – primary tumor size T1 (n = 44)vs. T2 (n = 40) 5353.64 11.54 0.033 21 .9 28 73.93 7.13 0.038 20 .5 5343.98 6 .26 0.051...

Ngày tải lên: 18/06/2014, 15:20

... (fr.4 02- 478) D 0.039 0 .20 6 0.1 52 8,931 C3 (fr.6 72- 747) D 0.039 0 .23 8 0.106 8,9 42 APOA2 (fr .24 -100) D 0. 024 0.084 0 .20 4 8,973 - D 0. 024 0.099 0.193 9,419 APOC3 (fr .21 -99) I 0. 024 0.084 0 .20 7 9,519 ... Consensus on the Primary Therapy of Early Breast Cancer 20 09. Ann Oncol 20 09, 20 :1319-1 329 . 4. Hanash S: Disease proteomics. Nature 20 03, 422 :22 6 -23 2. 5. Wulfkuhle JD, Liotta LA, Petricoin EF: ... therapy Only surgery 2, 7 42 0.050 0.118 0 .27 5 3 ,26 3 FGA (fr.576-604) I 0.053 0.084 0.506 3,3 02 - I 0.039 0 .23 8 0.150 3,9 92 - D 0.039 0.136 0.1 82 4,038 - I 0.099 0.099 0.510 4, 524 APP (fr.6 72- 713) D 0.053...

Ngày tải lên: 18/06/2014, 16:20

... June C, Zhang PJ: Targeting HER -2/ neu in early breast cancer development using dendritic cells with staged interleukin- 12 burst secretion. Cancer Res 20 07, 67:18 42- 18 52. 8. Matkowski R, Gisterek ... human breast cancer. Breast 20 08, 17:604-610. 10. Kominsky SL, Hobeika AC, Lake FA, Torres BA, Johnson HM: Down- regulation of neu/HER -2 by interferon-gamma in prostate cancer cells. Cancer Res 20 00, ... progressed to HER -2/ neu negative breast cancer under HER -2/ neu-specific immune pressure. Methods: We conducted a pilot study in patients with HER -2/ neu positive and HER -2/ neu negative breast cancers as...

Ngày tải lên: 18/06/2014, 19:20

... deterioration (n = 23 ) 79.3 56.9 -22 .5 (10.8) 73.0 59.8 -13 .2 (11 .2) -1.17 0. 72 0.57 -0.15 (0 .29 ) -0. 52 Small deterioration (n = 14) 75.6 67.3 -8.3 (0.0) 74.4 69.4 -5.1 ( 12. 0) -0. 42 0.73 0. 72 -0.01 (0.18) -0.05 No ... 0.7 (8.8) 0.08 0. 82 0. 82 0.00 (0 .21 ) 0.01 Small improvement (n = 28 ) 71 .2 80.1 8.3 (0.0) 70.9 77.7 6.1 (7.7) 0.79 0.78 0.80 0. 02 (0.14) 0.16 Moderate-large improvement (n = 72) 58 .2 85.6 27 .4 (11.9) 65.0 ... for Research and Treatment of Cancer. Eur J Cancer 20 02, 38(Suppl 4):S 125 -133. 32. McLachlan SA, Devins GM, Goodwin PJ: Validation of the Euro- pean Organization for Research and Treatment of Cancer Quality...

Ngày tải lên: 18/06/2014, 19:20

... progressed to HER -2/ neu negative breast cancer under HER -2/ neu-specific immune pressure. Methods: We conducted a pilot study in patients with HER -2/ neu positive and HER -2/ neu negative breast cancers as ... Massey Cancer Center, 401 College Street, Richmond VA 23 298, USA. 2 Department of Pathology, Virginia Commonwealth University Massey Cancer Center, 120 0 E. Marshall Street, Richmond VA 9806 62, USA. 3 Department ... patients Of 12 patients with HER -2/ neu negative breast cancers (stages I-IIIA) ten patients showed HER -2/ neu-specific IFN-g producing T cell responses (Figure 1A). All three patients with HER -2/ neu...

Ngày tải lên: 20/06/2014, 03:20

... 3) Polymer PCNP 29 3 .2 ± 3.6 0.1 72 9.76 65.08 -48.70 ± 3.11 PCL PFNP 20 1.7 ± 10.1 0.096 10. 02 69.10 - 12. 50 ± 0.86 PCL/F68 CCNP 28 1 .2 ± 5.5 0.145 -35.70 ± 2. 99 PCL CFNP 22 2.7 ± 5.4 0.133 -20 .50 ± 1.34 PCL/F68 Note: ... drugs. Biomaterials 26 , 27 13 27 22 (20 05) 27 . M.P. Desai, V. Labhasetwar, E. Walter, R.J. Levy, G.L. Amidon, The mechanism of uptake of biodegradable microparticles in Caco -2 cells is size dependent. ... concentration of 0. 025 , 0 .25 , 2. 5, 10, and 25 lg/mL and empty PCL/Pluronic F68 (PCL/F68) nanoparticles with the same nanoparticle concentrations of 0 .25 , 2. 5, 25 , 100, and 25 0 lg/ml, respectively...

Ngày tải lên: 22/06/2014, 00:20

... III 1 .22 1 .23 (1.16, 1 .29 ) 1 .20 1 .20 (1.06, 1.35) IV n/a n/a 2. 25 2. 29 (2. 11, 2, 47) Year of diagnosis 1996-1999 1.00 1.00 1.00 1.00 20 00 -20 02 0.96 0.94 (0.90, 0.99) 1.01 0.98 (0. 92, 1.04) ... 22 20 (22 .8) 1865 (24 .8) 355 (16.1) Estrogen Receptor Positive 420 5 (43 .2) 3 423 (45.5) 7 82 (35.5) <0.001 Negative 20 39 (21 .0) 1433 (19.1) 606 (27 .5) Other & Unknown 3477 (35.8) 26 62 ... 1.04) 0.77 (0.68, 0.88) 0. 92 (0.78, 1.08) III 1 .24 (1.17, 1.31) 1 .24 (1.11, 1.39) 1 .24 (1.09, 1.41) 1.06 (0.90, 1 .26 ) IV n/a n/a 2. 20 (2. 02, 2. 40) 1.73 (1.50, 2. 00) Year of diagnosis 1996-1999...

Ngày tải lên: 08/08/2014, 17:20

... after neo-adjuvant chemotherapy in locally advanced breast cancer - a prospective study Chintamani 1 ,2* , Megha Tandon 1 ,2 , Ashwani Mishra 2, 3 , Usha Agarwal 2, 3 , Sunita Saxena 2, 3 Abstract Background: ... of SLNB Breslin TM et al [19 ,20 ] II/III Blue dye+/_radio colloids 51 25 84.3 12 Accurate Nason KS et al [21 ] T1-T4, N0 Blue dye +radio colloid 15 9 86.7 33 Inaccurate Julien TB et al [22 ] I/II, palpable ... with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 20 02, 9 :24 3 -24 7. doi:10.1186/1477-7819-9-19 Cite this article as: Chintamani...

Ngày tải lên: 09/08/2014, 01:24

... (%) Pre-Menopausal 1 (2. 3%) 0 Peri-Menopausal 2 (4.6%) 2 (5%) Post-Menopausal 41 (93 .2% ) 41 (95%) Tumor Size: mean (range) 1 .2 cm (0 .2- 2.8 cm) 1.0 cm AJCC Class: n (%) Tis 12 (27 .3%) 0 T1a 1 (2. 3%) 9 (21 %) T1b ... with the Mammosite breast brachytherapy applicator in women with early -stage breast cancer treated with breast- conserving therapy. Int J Radiat Oncol Biol Phys 20 03, 55 :28 9 -29 3. 22 . Pawlik TM, Perry ... Grade 2 Grade 3 Blistering 2 (4.5%) 0 1 (2. 3%) Bruising 1 (2. 3%) 0 0 Desquamation, Dry 1 (2. 3%) 1 (2. 3%) 0 Desquamation, Moist 1 (2. 3%) 0 2 (4.5%) Drainage, Serosanguinous 1 (2. 3%) 0 0 Dry Skin (Breast) ...

Ngày tải lên: 09/08/2014, 01:24

Ngày tải lên: 09/08/2014, 03:21

Ngày tải lên: 09/08/2014, 03:21

Ngày tải lên: 09/08/2014, 04:21